CD8A and neoplasm: Considering the changes in the TME between non-tumor and HCC (87, 88), our Cluster C1 signature has shown a predictive advantage in distinguishing the specific eHCC immune cell (CD8 Tem and CTLs) infiltration level from non-tumor samples.